Made to do more.
- Infasurf has the highest SP-B to phospholipid ratio of any exogenous surfactant1
- SP-B plays a critical role in overall surfactant effectiveness.4,5
| Infasurf® (calfactant)1,2 |
Curosurf® (poractant alfa)1,5 |
Survanta® (beractant)1,6 |
|
|---|---|---|---|
| Type | Natural - Bovine | Natural - Porcine | Semi-Synthetic - Bovine |
| SP-B Content (% of total Phospholipids) |
0.74% | 0.59% | 0.04% |
| Initial Dose | 3 mL/kg | 2.5 mL/kg | 4 mL/kg |
| Dosing Frequency | 12 Hours | 12 Hours | 6 Hours |
Disclaimer:
Preclinical and biologic testing do not predict clinical effects.
Table does not imply clinical superiority of Infasurf® (calfactant).
Safety Information:
Infasurf (calfactant) should be administered under the supervision of clinicians experienced in the acute care of newborn infants with respiratory failure who require intubation. Rapid and substantial increases in blood oxygenation and improved lung compliance often follow Infasurf instillation/ Close clinical monitoring and surveillance following administration may be needed to adjust oxygen therapy and ventilator pressures appropriately.
References:
1. Notter RH. Lung Surfactants. Michael Dekker, New York, 2000, pp 171-232; 319-345. 2. Swartz D, Klein W, Row S, et al. Comparison of dynamic viscosities of lung surfactant drugs. Poster presented Hot Topics. 2017. 4. Mizuno K, Ikagami M, Chen C-M, et al. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res. 1995;37:271-276. 5. Hall SB, Vemkitaraman AR, Whitsett JA, et al. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis. 1992;145:24-30. 6. Kim K, Choi S, Zell Z, et al. Effect of cholesterol nanodomains on monolayer morphology and dynamics. Proc Natl Acad Sci USA. 2013;110:E3054-60.
